Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
NCT05332483Phase 1Terminated
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of megestrol in endometrioid endometrial carcinoma (EEC), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Overall Response Rate at 2 years. Started Jul 2022; status: terminated.
02
Drugs
megestrol
03
Conditions
endometrioid endometrial carcinoma (EEC)
Beyond the preview
Go deeper on NCT05332483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05332483.